Upstream Bio

IPO

Homepage

Public · Waltham, United States · Founded 2021 · $400.0M raised

Employees
51–200
Founded
2021
Business Model
B2B
Total Funding
$400.0M
Last Round
$200.0M Series BJun 2023
Rounds
2
Type
Public

About

Upstream Bio is a clinical-stage biotechnology company developing verekitug, the only known TSLP receptor antagonist in clinical development for inflammatory diseases. The company has advanced verekitug into three Phase 2 clinical trials across chronic rhinosinusitis with nasal polyps, severe asthma, and COPD, with an experienced team focused on severe respiratory diseases.

Summary

Upstream Bio is a Biotech company based in Waltham, United States, founded in 2021. It has raised $400.0M in total across 2 rounds, most recently a $200.0M Series B round in Jun 2023. Investors include OrbiMed, Maruho Co., Ltd. and Enavate Sciences.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

IPOOct 2024
$293.0M

Sign up to see all 3 rounds

Series A through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Upstream Bio on Indexed.vc
<a href="https://indexed.vc/companies/upstream-bio"><img src="https://indexed.vc/api/badge/company/upstream-bio" alt="Upstream Bio on Indexed.vc" width="260" height="76" /></a>